A5101709802- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Transplantation: Methods and Outcomes
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Pneumocystis jirovecii pneumonia detection and treatment
- Mesenchymal stem cell research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Diagnosis and Treatment of Venous Diseases
- Cancer Risks and Factors
- Blood properties and coagulation
- Nosocomial Infections in ICU
- Cerebrovascular and Carotid Artery Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Organ Transplantation Techniques and Outcomes
Queen Alexandra Hospital
2024
Aurora Health Care
2021-2024
Aurora St. Luke's Medical Center
2024
University of Lahore
2022
University of Cincinnati Medical Center
2020-2021
University of Cincinnati
2017-2020
University of Kentucky
2012-2016
Markey Cancer Center
2012-2016
The Barbara Ann Karmanos Cancer Institute
2009-2011
Wayne State University
2007-2011
Both acute and chronic graft-versus-host disease (GVHD) are major causes of morbidity mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). The optimal pharmacological regimen for GVHD prophylaxis is unclear, but combinations a calcineurin inhibitor (cyclosporin or tacrolimus [Tac]) an antimetabolite (methotrexate mycophenolate mofetil [MMF]) typically used. We retrospectively evaluated the clinical outcomes 414 consecutive who underwent AHSCT from...
Abstract There is a lack of large comparative study on the outcomes reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood Marrow Transplant Research who received first RIC allo-transplant between 2001 2015 were studied. Patients excluded if they cord blood or identical twin transplant, total body irradiation conditioning,...
Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality in patients undergoing unrelated hematopoietic stem cell transplantation. We prospectively evaluated the efficacy intermediate-dose rabbit anti-thymocyte globulin (Thymoglobulin® total 4.5 mg/kg given over days −3, −2, −1) combination with tacrolimus sirolimus for prevention aGVHD. enrolled 47 recipients who underwent Patients received daily granulocyte colony-stimulating factor starting on day +6 until...
Blinatumomab, a bispecific T-cell engager monoclonal antibody used to manage Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) can be treat patients by inducing graft versus reaction post allogeneic hematopoietic stem cell transplantation, feature which it was bone marrow this drug not aimed do.
Abstract Thrombosomes are trehalose‐stabilized, freeze‐dried group O platelets with a 3‐year shelf life. They can be stockpiled, rapidly reconstituted, and infused regardless of the recipient's blood type. thus represent potential alternative platelet transfusion strategy. The present study assessed safety early signals efficacy in bleeding thrombocytopenic patients. We performed an open‐label, phase 1 single doses allogeneic at three dose levels cohorts, each consisting eight patients who...
Abstract Background Evaluations of oral vancomycin prophylaxis (OVP) against Clostridioides difficile have been reported in stem cell transplant populations with short follow-up periods. The longest known duration standardized post-OVP is 90 days within an allogeneic population. In 2017, we implemented OVP 125 mg twice daily autologous (ASCT) recipients beginning the day admission and continued until discharge. Methods Patients who received ASCT our institution between 1 January 2012 31...
We enrolled 15 patients in this phase I dose de-escalation trial. Twelve are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). secondary endpoints were evaluate complete response (CR), overall (OR) duration. All receiving autologous stem cell transplant (ASCT) eligible registered between D+30 D+120 after ASCT. A maximum number 8 cycles B planned. Two evaluable level (L) 1 received therapeutic 1·3 mg/m2 intravenously on...
Objective: To compare the sonographic findings of atherosclerotic changes in carotid arteries diabetic and non-diabetic individuals. Material & Methods: A cross-sectional study 62 individuals was conducted from 11 November 2021 to 20 March 2022 at Radiology Department District Head Quarter Hospital, Faisalabad, Pakistan. The ultrasound with a TOSHIBA MX Doppler machine, using linear probe transducer frequency 5-12.5MHz performed both participants. Results: mean value CIMT patients 0.6839...
Abstract Introduction Granulomatosis with polyangiitis (GPA) and tuberculosis (TB) are both granulomatous disease which can have similar clinical manifestations organ involvement. This report discusses a case of such overlapping presentation anti-neutrophil cytoplasmic antibodies (ANCA) positivity, leading to diagnostic uncertainty. Case description A 40-year-old female who lived in sub-Saharan Africa until two years ago presented month history general malaise, significant weight loss,...
Introduction: Initial continuous intravenous (CIV) tacrolimus (0.03 mg/kg/day based on ideal body weight [IBW]) has been favored for graft versus host disease (GVHD) prevention in allogeneic stem cell transplant patients due to the consistent, steady-state degree of immunosuppression; however, this method poses many logistical challenges. We implemented intermittent (IIV) at a starting dose 0.015 mg/kg IBW twice daily over 4 h. To our knowledge is first retrospective comparison CIV IIV...
Key Clinical Message IgG4‐ RD can also present in the skeletal muscle, mimicking several other diseases. It is unusual for this relatively new classification of diseases to muscles and be mistakenly diagnosed as autoimmune rendering a delay appropriate management progression disease.
e19074 Background: Hypomethylating agents (HMA) such as decitabine and azacitidine are frontline therapies for myelodysplastic syndrome (MDS) acute myeloid leukemia (AML). Limited data exist on subsequent cardiovascular (CV) events. Johnson et al. reported 170 patients receiving HMA + venetoclax with a CV event rate of 20%. Aims: To investigate the incidence events in HMA. Methods: We analyzed adult AML MDS > 1 dose or from 1/2018-12/2020. New were defined new atrial fibrillation,...
Higher absolute lymphocyte count at day 30 (ALC 30) after allogeniec hematopoietic stem cell transplant (HSCT) has been associated with better overall survival (OS). This largely evaluated in small retrospective studies cyclosposrine and methotrexate for graft vs. host disease (GVHD) prophylaxis. ALC its impact on patient (pt) outcomes tacrolimus (Tac) mycophenolate mofetil (MMF) is unknown. We retrospectively a cohort of 414 consecutive pts between January 2005 June 2010 Karmanos Cancer...
7078 The most common (10–15%) chromosomal abnormality found in myelodysplastic syndromes (MDS) is an interstitial deletion of the long arm chromosome 5 (del(5q)). recent finding that lenalidomide efficacious for MDS patients with del(5q) as either sole or part a complex karyotype has focused renewed interest prognostic characteristics these patients. We analyzed 189 del(5q), 70 having isolated and 119 additional abnormalities. median survival patient was 2.45 years those abnormalities 0.63...